Dr. John DiPersio Selected to Give the Prestigious E. Donnall Thomas Lecture (Links to an external site)

Dr. John DiPersio Selected to Give the Prestigious E. Donnall Thomas Lecture
John DiPersio, MD, PhD, Professor Medicine in the Division of Oncology will give the 2024 E Donnall Thomas lecture at the ASTCT/CIBMTR Tandem Meetings in San Antonio. The E. Donnall Thomas Lecture recognizes an eminent physician or scientist, either a clinician or an investigator, who has contributed meritoriously to the advancement of knowledge in blood […]

Oncology Faculty Members Receive Siteman Investment Program Research Grants

Oncology Faculty Members Receive Siteman Investment Program Research Grants
Melissa Reimers, Nikolaos Trikalinos, Kian-Huat Lim, Milan Chheda and Christopher Maher from the Division of Oncology received Siteman Investment Program funding for their research. Dr. Reimers, Associate Professor of Medicine, will assess the safety and tolerability of dapagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor used to treat diabetes and heart failure, in patients with high-risk […]

Phase 3 Trial in Breast Cancer Published in JAMA Oncology (Links to an external site)

Phase 3 Trial in Breast Cancer Published in JAMA Oncology
Cynthia Ma , lead author and Professor of Medicine in the Division of Oncology along with her colleagues Kiran Vij, Jeremy Hoog, Mark Watson and Erika Crouch in the Department of Pathology investigated the role of neoadjuvant anastrazole, fulvestrant or the combination in a multi-institutional trial. The trial did not find a benefit of fulvestrant […]

Fehniger Receives Grant from Rising Tide Foundation for Cancer Research and the Melanoma Research Alliance (Links to an external site)

Fehniger Receives Grant from Rising Tide Foundation for Cancer Research and the Melanoma Research Alliance
Dr. Fehniger, along with Alice Zhou (Division of Oncology), George Ansstas (Division of Oncology), and Ryan Fields (Department of Medicine) have received a $1.5 million grant to support a phase 1 trial of immunotherapy for melanoma. The study will treat patients with melanoma with natural killer cell-based therapy developed at Washington University for treatment of […]

Grant Challen, PhD Receives Prestigious LLS Career Development Achievement Award (Links to an external site)

Grant Challen, PhD Receives Prestigious LLS Career Development Achievement Award
Dr. Challen, Professor of Medicine in the Division of Oncology is a 2023 Leukemia & Lymphoma Society-Career Development Program Scholar Achievement Awardee. Dr. Challen’s laboratory research aims to determine how disruption of the chemical compounds that direct our genome leads to the development of blood cancers including important work in understanding how mutations in the […]

Study lead by Washington University scientists reveal important roles of the epigenome in the way cancer forms, grows and spreads. (Links to an external site)

Study lead by Washington University scientists reveal important roles of the epigenome in the way cancer forms, grows and spreads.
This collaborative study, published in Nature on Nov 1, 2023 involved researchers from the Divisions of Oncology, Department of Surgery, McDonnell Genome Institute, Siteman Cancer Center, Department of Radiation Oncology, Department of Neurologic Surgery, Department of Otolaryngology, Department of Obstetrics & Gynecology, and Department of Genetics at Washington University. Scientists discovered specific epigenetic changes that […]

Two Hematology-Oncology Fellows Receive 2023 Knowlton Incentive for Excellence Award

Two Hematology-Oncology Fellows Receive 2023 Knowlton Incentive for Excellence Award
Rigoberto De Jesus Pizarro and Joshua Siner, both third year Hematology-Oncology Fellows at Washington University School of Medicine are recipients of the 2023 Knowlton Incentive for Excellence Award. The awards recognize and support fellows who exemplify a compassionate spirit combined with outstanding knowledge and skill.Dr. Siner has clinical and research interests in classical hematology with […]

Three New Clinical Trials of Immunotherapy for Pancreatic Ductal Adenocarcinoma Beginning at Siteman Cancer Center (Links to an external site)

Three New Clinical Trials of Immunotherapy for Pancreatic Ductal Adenocarcinoma Beginning at Siteman Cancer Center
A $10.9 Million SPORE Grant for Pancreas Cancer expands on research funded by a prior pancreas cancer SPORE grant and various studies undertaken at Washington University. It targets novel therapeutic targets for the management of pancreatic ductal adenocarcinoma (PDAC), recognized as the most lethal variant of pancreatic cancer. Currently, the five-year survival rate for PDAC […]